Gambaran Umum
Medexus Pharmaceuticals Inc. is headquartered in Canada and operates primarily within the pharmaceutical industry. The company is engaged in the development and commercialization of innovative prescription products tailored primarily to the North American market, with particular emphasis on Canada and the United States. Medexus focuses on therapeutic areas that include rheumatology, auto-immune diseases, oncology, and specialty care. Key projects include enhanced versions of existing drugs and innovative treatment options designed to improve patient outcomes and compliance. The company has carved a niche by improving drug delivery methods and formulating better versions of existing medications, thereby distinguishing itself as a leader in the enhancement of therapeutic efficacy and patient usability in its targeted domains.
Skor Kualitas, Nilai, dan Momentum
Kartu ini menunjukkan skor Kualitas, Nilai, dan Momentum untuk perusahaan tersebut.
Laporan Laba Rugi: Pendapatan, Laba Operasional, Laba Bersih
- Nilai revenue untuk Medexus Pharmaceuticals Inc. per 2025 Jun 30 adalah 105.66 MM.
- Nilai operating income untuk Medexus Pharmaceuticals Inc. per 2025 Jun 30 adalah 8.44 MM.
- Nilai net income untuk Medexus Pharmaceuticals Inc. per 2025 Jun 30 adalah 0.81 MM.
Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
2025-06-30 | 105.66 | 8.44 | 0.81 |
2025-03-31 | 108.33 | 11.92 | 2.25 |
2024-12-31 | 109.54 | 15.04 | 3.56 |
2024-09-30 | 104.76 | 12.82 | 2.29 |
2024-06-30 | 108.78 | 12.28 | 1.09 |
2024-03-31 | 113.05 | 12.79 | -0.21 |
2023-12-31 | 115.72 | 12.79 | 5.88 |
2023-09-30 | 119.25 | 14.49 | 4.91 |
2023-06-30 | 116.61 | 13.27 | 3.27 |
2023-03-31 | 108.10 | 8.49 | 1.22 |
2022-12-31 | 99.73 | 4.96 | -10.92 |
2022-09-30 | 92.27 | 1.38 | -10.56 |
2022-06-30 | 82.48 | -5.15 | 2.31 |
2022-03-31 | 76.70 | -12.38 | -2.88 |
2021-12-31 | 74.08 | -15.26 | -8.08 |
2021-09-30 | 77.06 | -12.96 | -19.71 |
2021-06-30 | 76.93 | -8.28 | -31.42 |
2021-03-31 | 79.66 | 0.73 | -28.26 |
2020-12-31 | 79.28 | 5.88 | -19.23 |
2020-09-30 | 68.86 | 3.02 | -8.57 |
2020-06-30 |
Laporan Laba Rugi: EPS
Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
2025-06-30 | ||
2025-03-31 | ||
2024-12-31 | 0.15 | 0.14 |
2024-09-30 | 0.09 | 0.09 |
2024-06-30 | 0.05 | 0.05 |
2024-03-31 | ||
2023-12-31 | 0.28 | 0.26 |
2023-09-30 | 0.24 | 0.24 |
2023-06-30 | 0.16 | 0.16 |
2023-03-31 | 0.06 | 0.06 |
2022-12-31 | -0.55 | -0.55 |
2022-09-30 | -0.53 | -0.54 |
2022-06-30 | 0.12 | 0.11 |
2022-03-31 | -0.15 | -0.15 |
2021-12-31 | -0.43 | -0.43 |
2021-09-30 | -1.12 | -1.13 |
2021-06-30 | -1.92 | -1.91 |
2021-03-31 | -1.86 | |
2020-12-31 | -1.34 | -1.34 |
2020-09-30 | -0.60 | -0.61 |
2020-06-30 | -0.46 | -0.46 |
Arus Kas: Operasi, Investasi, Pendanaan
- Nilai cash from operating activities untuk Medexus Pharmaceuticals Inc. per 2025 Jun 30 adalah 19.76 MM.
- Nilai cash from investing activities untuk Medexus Pharmaceuticals Inc. per 2025 Jun 30 adalah -7.87 MM.
- Nilai kas dari aktivitas pendanaan untuk Medexus Pharmaceuticals Inc. per 2025 Jun 30 adalah -11.00 MM.
Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
2025-06-30 | 19.76 | -7.87 | -11.00 |
2025-03-31 | 24.03 | -6.00 | 0.80 |
2024-12-31 | 23.36 | -4.48 | -18.33 |
2024-09-30 | 22.20 | -5.75 | -29.03 |
2024-06-30 | 22.69 | -3.36 | -26.57 |
2024-03-31 | 18.71 | -3.48 | -23.05 |
2023-12-31 | 20.97 | -3.63 | -18.49 |
2023-09-30 | 13.22 | -2.42 | -0.92 |
2023-06-30 | 6.79 | -2.15 | 3.91 |
2023-03-31 | -1.44 | -1.72 | 6.41 |
2022-12-31 | -1.52 | -2.86 | 4.27 |
2022-09-30 | -1.04 | -2.68 | 5.33 |
2022-06-30 | 1.62 | -2.47 | -1.90 |
2022-03-31 | -1.18 | -8.20 | 0.66 |
2021-12-31 | -0.76 | -16.75 | 16.51 |
2021-09-30 | -1.22 | -17.15 | 18.77 |
2021-06-30 | -4.77 | -17.58 | 23.59 |
2021-03-31 | 5.04 | -11.71 | 18.68 |
2020-12-31 | -0.45 | -30.93 | 23.59 |
2020-09-30 | 0.94 | -30.16 | 16.50 |
2020-06-30 |
Metrik Penilaian: PE, PriceToBook, PriceToTBV
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
Period End (TTM) | p/e | P/Book | P/TBV |
2025-06-30 | |||
2025-03-31 | |||
2024-12-31 | |||
2024-09-30 | |||
2024-06-30 | |||
2024-03-31 | |||
2023-12-31 | |||
2023-09-30 | |||
2023-06-30 | |||
2023-03-31 | |||
2022-12-31 | |||
2022-09-30 | |||
2022-06-30 | |||
2022-03-31 | |||
2021-12-31 | |||
2021-09-30 | |||
2021-06-30 | |||
2021-03-31 | |||
2020-12-31 | |||
2020-09-30 | |||
2020-06-30 |
Metrik Penilaian: EBitToEv, EBit3YrAvgToEv
Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
2025-06-30 | ||
2025-03-31 | ||
2024-12-31 | ||
2024-09-30 | ||
2024-06-30 | ||
2024-03-31 | ||
2023-12-31 | ||
2023-09-30 | ||
2023-06-30 | ||
2023-03-31 | ||
2022-12-31 | ||
2022-09-30 | ||
2022-06-30 | ||
2022-03-31 | ||
2021-12-31 | ||
2021-09-30 | ||
2021-06-30 | ||
2021-03-31 | ||
2020-12-31 | ||
2020-09-30 | ||
2020-06-30 |
Efektivitas Manajemen
- roa untuk Medexus Pharmaceuticals Inc. pada 2025 Jun 30 adalah 0.02.
- roe untuk Medexus Pharmaceuticals Inc. pada 2025 Jun 30 adalah 0.02.
- roic untuk Medexus Pharmaceuticals Inc. pada 2025 Jun 30 adalah 0.02.
- croic untuk Medexus Pharmaceuticals Inc. pada 2025 Jun 30 adalah 0.17.
- ocroic untuk Medexus Pharmaceuticals Inc. pada 2025 Jun 30 adalah 0.22.
Period End (TTM) | ROA | ROE | ROIC (Tingkat Pengembalian Investasi Modal) | CROIC | OCROIC |
2025-06-30 | 0.02 | 0.02 | 0.02 | 0.17 | 0.22 |
2025-03-31 | 0.02 | 0.07 | 0.05 | 0.00 | 0.32 |
2024-12-31 | 0.01 | 0.12 | 0.03 | -0.17 | 0.29 |
2024-09-30 | 0.01 | 0.11 | 0.01 | -0.09 | 0.29 |
2024-06-30 | 0.04 | -0.01 | 0.07 | -0.01 | 0.26 |
2024-03-31 | 0.04 | 0.38 | 0.07 | -0.01 | 0.26 |
2023-12-31 | 0.03 | 0.29 | 0.05 | 0.11 | 0.14 |
2023-09-30 | 0.02 | 0.19 | 0.03 | 0.09 | 0.07 |
2023-06-30 | -0.08 | 0.19 | 0.04 | 0.10 | 0.08 |
2023-03-31 | -0.08 | 0.07 | 0.01 | 0.03 | -0.02 |
2022-12-31 | -0.08 | -0.44 | -0.14 | 0.02 | -0.01 |
2022-09-30 | 0.02 | -0.44 | -0.14 | 0.02 | -0.01 |
2022-06-30 | -0.02 | 0.20 | 0.03 | -0.04 | 0.02 |
2022-03-31 | -0.05 | -0.16 | -0.04 | -0.12 | -0.02 |
2021-12-31 | -0.11 | -1.88 | -0.11 | 0.00 | -0.02 |
2021-09-30 | -0.16 | -1.06 | -0.26 | 0.02 | -0.08 |
2021-06-30 | -0.25 | -1.54 | -0.67 | 0.06 | -0.10 |
2021-03-31 | -0.23 | -1.16 | -0.45 | 0.21 | 0.08 |
2020-12-31 | -0.17 | -0.64 | -0.37 | -0.10 | -0.01 |
2020-09-30 | -0.08 | -0.25 | -0.14 | -0.15 | 0.02 |
2020-06-30 | -0.06 | -0.19 | -0.13 | -0.26 | 0.03 |
Gross Margins
- marjin kotor untuk Medexus Pharmaceuticals Inc. pada 2025 Jun 30 adalah 0.59.
- marjin bersih untuk Medexus Pharmaceuticals Inc. pada 2025 Jun 30 adalah 0.02.
- marjin operasi untuk Medexus Pharmaceuticals Inc. pada 2025 Jun 30 adalah 0.11.
- Margin Kotor
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Margin Keuntungan Bersih
- Margin Bersih (juga dikenal sebagai Margin Keuntungan) adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Bersih. Perhitungannya adalah Pendapatan Bersih / Pendapatan.
- Margin Operasi
- Margin Operasi adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Operasi. Perhitungannya adalah Pendapatan Operasi / Pendapatan.
Period End (TTM) | Margin Kotor | Margin Keuntungan Bersih | Margin Operasi |
2025-06-30 | 0.59 | 0.02 | 0.11 |
2025-03-31 | 0.58 | 0.03 | 0.14 |
2024-12-31 | 0.58 | 0.02 | 0.12 |
2024-09-30 | 0.58 | 0.01 | 0.11 |
2024-06-30 | 0.58 | 0.05 | 0.11 |
2024-03-31 | 0.58 | 0.05 | 0.11 |
2023-12-31 | 0.59 | 0.04 | 0.12 |
2023-09-30 | 0.60 | 0.03 | 0.11 |
2023-06-30 | 0.61 | 0.03 | 0.11 |
2023-03-31 | 0.61 | 0.01 | 0.08 |
2022-12-31 | 0.61 | -0.11 | 0.01 |
2022-09-30 | 0.60 | -0.11 | 0.01 |
2022-06-30 | 0.57 | 0.03 | -0.06 |
2022-03-31 | 0.57 | -0.04 | -0.16 |
2021-12-31 | 0.56 | -0.11 | -0.21 |
2021-09-30 | 0.57 | -0.26 | -0.17 |
2021-06-30 | 0.57 | -0.41 | -0.11 |
2021-03-31 | 0.60 | -0.35 | 0.01 |
2020-12-31 | 0.59 | -0.24 | 0.10 |
2020-09-30 | 0.61 | -0.12 | 0.04 |
2020-06-30 | 0.71 | -0.08 | 0.03 |
Pengenal dan Deskriptor
Kunci Indeks Pusat (CIK) |